The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The post hoc analysis used data from the phase 2/3 ...

P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio A non-inferiority comparison between ...

Credit: Getty Images. The BLA is supported by data from the pivotal PULSAR and PHOTON trials. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

On July 1, Samsung Bioepis Co., Ltd. announced that the FDA has approved PYZCHIVA (ustekinumab-ttwe), a biosimilar referencing STELARA (ustekinumab). PYZCHIVA is approved for the treatment of moderate ...

Findings of the PANORAMA randomized clinical trial show that when patients with severe nonproliferative diabetic retinopathy were treated with intravitreal aflibercept, severity improved over 100 ...

As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a motion seeking to establish a multi-district litigation (“MDL”) encompassing the aflibercept BPCIA ...